par Zardavas, Dimitros 
;Pugliano, Lina ;Piccart-Gebhart, Martine
Référence Future oncology, 9, 8, page (1105-1119)
Publication Publié, 2013-08
;Pugliano, Lina ;Piccart-Gebhart, Martine Référence Future oncology, 9, 8, page (1105-1119)
Publication Publié, 2013-08
Article révisé par les pairs
| Résumé : | Breast cancer oncology represents one of the disciplines where personalized cancer medicine has been most actively pursued. The class-discovery studies conceptually advanced the field, underlining the molecular heterogeneity governing this common disease. The advent of high-throughput molecular profiling technologies holds great promise for the advance of all aspects of personalized cancer medicine, namely accurate prognostication, prediction of response to common systemic therapies and individualized monitoring of the disease. Moreover, an ever-expanding arsenal of targeted therapeutic compounds under clinical development, coupled with emerging powerful tools for comprehensive molecular and functional characterization, pose significant promise for improved clinical outcomes for breast cancer patients. Interrogation of the germline genetic variation offers further promise towards tailoring of breast cancer management. Well-conducted prospective validation studies are needed if breast cancer personalized therapy is to transform from a dream into a reality. © 2013 Future Medicine Ltd. |
